Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Aug;42(8):e137.
doi: 10.2337/dci19-0026.

Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657-664

Barbara H Braffett  1 , Samuel Dagogo-Jack  2 , Ionut Bebu  3 , William I Sivitz  4 , Mary Larkin  5 , Orville Kolterman  6 , John M Lachin; DCCT/EDIC Research Group
Affiliations
Comment

Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657-664

Barbara H Braffett et al. Diabetes Care. 2019 Aug.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Snaith JR, Holmes-Walker DJ, Greenfield JR. Comment on Braffett et al. Association of insulin dose, cardiometabolic risk factors, and cardiovascular disease in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC study. Diabetes Care 2019;42:657–664 (Letter). Diabetes Care 2019;42:e135–e136. DOI: 10.2337/dc19-0730 - PMC - PubMed
    1. Schauer IE, Snell-Bergeon JK, Bergman BC, et al. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes 2011;60:306–314 - PMC - PubMed
    1. Braffett BH, Dagogo-Jack S, Bebu I, et al.; DCCT/EDIC Research Group . Association of insulin dose, cardiometabolic risk factors, and cardiovascular disease in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC study. Diabetes Care 2019;42:657–664 - PMC - PubMed
    1. Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol 2018;19:31–44 - PMC - PubMed
    1. Petrie JR, Chaturvedi N, Ford I, et al.; REMOVAL Study Group . Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017;5:597–609 - PMC - PubMed

Associated data